Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study

被引：14
|
作者：
Antia, Camila [1 ]
Hone, Natalie [1 ]
Gloster, Hugh [1 ]
机构：
[1] Univ Cincinnati, Dept Dermatol, 231 Albert Sabin Way, Cincinnati, OH 45229 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 77卷 / 05期
关键词：
CUTANEOUS SURGERY;
D O I：
10.1016/j.jaad.2017.05.038
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：967 / 968
页数：2
相关论文
共 50 条
  • [11] Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban, edoxaban - addition - EML
    SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 339 - 355
  • [12] New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
    Aguilar, Maria I.
    Kuo, Ruth S.
    Freeman, William D.
    NEUROLOGIC CLINICS, 2013, 31 (03) : 659 - +
  • [13] Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban
    Tsuruya, Yuri
    Nakanishi, Takeo
    Komori, Hisakazu
    Wang, Xinying
    Ishiguro, Naoki
    Kito, Tomoko
    Ikukawa, Kouji
    Kishimoto, Wataru
    Ito, Sumito
    Schaefer, Olaf
    Ebner, Thomas
    Yamamura, Norio
    Kusuhara, Hiroyuki
    Tamai, Ikumi
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) : 2524 - 2534
  • [14] Rivaroxaban, dabigatran and apixaban. New anticoagulants in operative urology [Rivaroxaban, dabigatran und apixaban. Neue antikoagulanzien in der operativen urologie]
    John A.
    Michel M.S.
    Der Urologe, 2014, 53 (6): : 893 - 903
  • [15] New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) and Vitamin K Antagonists: Incidence and Treatment Patterns in 2012 in France
    Maura, G.
    Billionnet, C.
    Weill, A.
    Ricordeau, P.
    Alla, F.
    Allemand, H.
    DRUG SAFETY, 2013, 36 (09) : 836 - 836
  • [16] HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN
    Deitelzweig, Steven
    Gupta, Kiran
    Nadkarni, Anagha
    Trocio, Jeffrey
    Lin, Jay
    Lingohr-Smith, Melissa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 805 - 805
  • [17] Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development
    Ufer, Mike
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (03) : 572 - 585
  • [18] Direct Oral Anticoagulants Increase Bleeding Risk Following Mohs Micrographic Surgery: A Prospective Study
    Juhasz, Margit
    Nguyen, Tuyet A.
    Gharavi, Nima M.
    DERMATOLOGIC SURGERY, 2024, 50 (09) : 874 - 876
  • [19] The role of the pathologist in the Mohs micrographic surgery: a retrospective study
    Espanol, I.
    Trias, I.
    Alegre, M.
    VIRCHOWS ARCHIV, 2019, 475 : S264 - S265
  • [20] Drug interactions of newer oral anticoagulants dabigatran, rivaroxaban, and apixaban with routinely used nonanticoagulant/antiplatelet drugs
    Sayani, S.
    Iqbal, O.
    Hoppensteadt, D.
    Fareed, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 897 - 897
12345